Weekly Recap | NOVARTIS AG +4.02%, oral MS drug meets Phase 3 goalWeekly Review·Sep 5 at 07:35 AMNVS0.00%
Weekly Recap | NOVARTIS AG -3.18%, consensus target above spotWeekly Review·Aug 29 at 06:06 AMNVS0.00%
